Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
This study will evaluate the efficacy, safety and pharmacokinetics of capecitabine (2000 mg/m2/day by mouth [po], day 1 pm-day 15 am every 3 weeks [q3w]), oxaliplatin (130 mg/m2 intravenously [iv], day 1 q3w) and bevacizumab (7.5 mg/kg iv, day 1 q3w) in patients with advanced and/or metastatic colorectal cancer.
创建时间：
2006-02-15
